Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

130 та иш

Иш: Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

  1. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

    Dai Fukumura, Jonas Kloepper, Zohreh Amoozgar +2

    Шарҳ мақола20183 иқтибос
    ABI

  2. F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic That Targets Both Murine and Human Ovarian Tumor Endothelial Cells <i>In vivo</i>

    Ira Winer, Shouyan Wang, Youg-Eun Koo Lee +6

    Мақола20102 иқтибос
    ABI

  3. Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines

    Shi Du, Hui Xiong, Cheng Xu +2

    Мақола20192 иқтибос
    ABI

  4. Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models

    Qiaohong Wang, Jingze Gao, Wen Di +1

    Мақола20202 иқтибос
    ABI

  5. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

    Zowi R. Huinen, Elisabeth J. M. Huijbers, Judy R. van Beijnum +2

    Шарҳ мақола20212 иқтибос
    ABI

  6. Angiopoietin inhibitors: A review on targeting tumor angiogenesis

    Parmar Digna, Madhavi Apte

    Шарҳ мақола20212 иқтибос
    ABI

  7. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

    Elizabeth Allen, Arnaud Jabouille, Lee B. Rivera +8

    Мақола20172 иқтибос
    ABI

  8. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis

    Lisa M. Coussens, Christopher L. Tinkle, Douglas Hanahan +1

    Мақола20002 иқтибос
    ABI

  9. Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma

    Thanh-Nhan Nguyen-Pham, Sung‐Hoon Jung, Manh-Cuong Vo +7

    Мақола20152 иқтибос
    ABI

  10. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations

    Р. В. Холоденко, Daniel Kalinovsky, Igor I. Doronin +2

    Шарҳ мақола20192 иқтибос
    ABI

  11. Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives

    Ruixue Zhang, Ho Lun Wong, Hui Xue +2

    Шарҳ мақола20162 иқтибос
    ABI

  12. Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

    Rakesh K. Jain

    Шарҳ мақола20132 иқтибос
    ABI

  13. Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling

    Raquel Batlle, Eva Andrés, Lorena González +5

    Мақола20192 иқтибос
    ABI

  14. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    James A. Bonner, Paul M. Harari, J. Giralt +14

    Мақола20062 иқтибос
    ABI

  15. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo +17

    Мақола20182 иқтибос
    ABI

  16. A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

    Magnus Lindskog, Anna Laurell, Anders Kjellman +17

    Мақола20202 иқтибос
    ABI

  17. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  18. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  19. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  20. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  21. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  22. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  23. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  24. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI

  25. Сарлавҳасиз

    Бошқа1 иқтибос
    ABI